Payment overview · 2025
General Payments
$617.84
43 reported records · 13 companies
Healthcare provider profile · identity verified
Derrick H Williams, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BEREA, KY · NPI 1780966408
Verified facts
What the public records show
CMS Open Payments records show Derrick H Williams, D.O. received $617.84 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.26 | 32.7% | 21 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $74.27 | 12.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.78 | 11.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.89 | 6.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.43 | 6.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.85 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.10 | 5.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.70 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.34 | 3.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.73 | 3.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.46 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.05 | 2.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.98 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.84 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $143.58 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.75 | 14 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $74.27 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.78 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.68 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 245 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
245 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 581 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 105 |
| Omeprazole | Omeprazole | 344 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 85 |
| Losartan Potassium | Losartan Potassium | 270 | 73 |
| Clonazepam | Clonazepam | 248 | 33 |
| Mounjaro | Tirzepatide | 245 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 47 |
| Montelukast Sodium | Montelukast Sodium | 206 | 51 |
| Lisinopril | Lisinopril | 205 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 50 |
| Metformin Hcl | Metformin Hcl | 189 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 54 |
| Carvedilol | Carvedilol | 163 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 44 |
| Alprazolam | Alprazolam | 144 | 22 |
| Furosemide | Furosemide | 143 | 38 |
| Potassium Chloride | Potassium Chloride | 142 | 42 |
| Pregabalin | Pregabalin | 141 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 25 |
| Ozempic | Semaglutide | 131 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 125 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 20 |
| Sertraline Hcl | Sertraline Hcl | 121 | 32 |
| Meloxicam | Meloxicam | 114 | 35 |
| Tramadol Hcl | Tramadol Hcl | 112 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 30 |
| Baclofen | Baclofen | 106 | 27 |
| Ondansetron Odt | Ondansetron | 106 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 24 |
| Ibuprofen | Ibuprofen | 102 | 23 |
| Buspirone Hcl | Buspirone Hcl | 100 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 30 |
| Methylprednisolone | Methylprednisolone | 97 | 77 |
| Trazodone Hcl | Trazodone Hcl | 97 | 29 |
| Jardiance | Empagliflozin | 96 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 26 |
| Fluconazole | Fluconazole | 88 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 16 |
| Promethazine Hcl | Promethazine Hcl | 83 | 17 |
| Simvastatin | Simvastatin | 80 | 23 |
| Eliquis | Apixaban | 78 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 19 |
| Januvia | Sitagliptin Phosphate | 75 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 23 |
| Diazepam | Diazepam | 72 | 11 |
| Valsartan | Valsartan | 72 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Linzess | Linaclotide | 66 | 19 |
| Famotidine | Famotidine | 60 | 21 |
| Celecoxib | Celecoxib | 59 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 55 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 55 | suppressed |
| Allopurinol | Allopurinol | 54 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 48 | 14 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Cefdinir | Cefdinir | 46 | 40 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Nystatin | Nystatin | 44 | 20 |
| Topiramate | Topiramate | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 33 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Prednisone | Prednisone | 31 | 13 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 11 |
| Atenolol | Atenolol | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Risperidone | Risperidone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Yuvafem | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.84 · 43 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, LEQVIO, MOUNJARO, NEXLETOL, Omnipod, QULIPTA, REXULTI, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error